CL2012002032A1 - Composición farmacéutica hospedador/huesped de administración inyectable intravenosa anestésica o sedante que comprende un hospedador de ciclodextrina o su forma modificada con un huesped de fármaco anestésico esteroide neuroactivo; método para inducir o mantener la anestesia o sedación; y uso para inducir la anestesia. - Google Patents

Composición farmacéutica hospedador/huesped de administración inyectable intravenosa anestésica o sedante que comprende un hospedador de ciclodextrina o su forma modificada con un huesped de fármaco anestésico esteroide neuroactivo; método para inducir o mantener la anestesia o sedación; y uso para inducir la anestesia.

Info

Publication number
CL2012002032A1
CL2012002032A1 CL2012002032A CL2012002032A CL2012002032A1 CL 2012002032 A1 CL2012002032 A1 CL 2012002032A1 CL 2012002032 A CL2012002032 A CL 2012002032A CL 2012002032 A CL2012002032 A CL 2012002032A CL 2012002032 A1 CL2012002032 A1 CL 2012002032A1
Authority
CL
Chile
Prior art keywords
host
induce
anesthesia
anesthetic
pharmaceutical
Prior art date
Application number
CL2012002032A
Other languages
English (en)
Inventor
Juliet Marguerite Goodchild
Colin Stanlev Goodchild
Benjamin James Boyd
Original Assignee
Goodchild Invest Pty Ltd
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goodchild Invest Pty Ltd, Univ Monash filed Critical Goodchild Invest Pty Ltd
Publication of CL2012002032A1 publication Critical patent/CL2012002032A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica hospedador/huésped de administración inyectable intravenosa anestésica o sedante que comprende un hospedador de ciclodextrina o su forma modificada con un huésped de fármaco anestésico esteroide neuroactivo; método para inducir o mantener la anestesia o sedación; y uso para inducir la anestesia.
CL2012002032A 2010-01-21 2012-07-20 Composición farmacéutica hospedador/huesped de administración inyectable intravenosa anestésica o sedante que comprende un hospedador de ciclodextrina o su forma modificada con un huesped de fármaco anestésico esteroide neuroactivo; método para inducir o mantener la anestesia o sedación; y uso para inducir la anestesia. CL2012002032A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US38531810P 2010-09-22 2010-09-22

Publications (1)

Publication Number Publication Date
CL2012002032A1 true CL2012002032A1 (es) 2012-12-21

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002032A CL2012002032A1 (es) 2010-01-21 2012-07-20 Composición farmacéutica hospedador/huesped de administración inyectable intravenosa anestésica o sedante que comprende un hospedador de ciclodextrina o su forma modificada con un huesped de fármaco anestésico esteroide neuroactivo; método para inducir o mantener la anestesia o sedación; y uso para inducir la anestesia.

Country Status (27)

Country Link
US (2) US8697678B2 (es)
EP (1) EP2525798B1 (es)
JP (1) JP5930311B2 (es)
KR (1) KR101747476B1 (es)
CN (1) CN102802635B (es)
AU (1) AU2011207103B2 (es)
BR (1) BR112012017800B1 (es)
CA (1) CA2786762C (es)
CL (1) CL2012002032A1 (es)
CY (1) CY1119947T1 (es)
DK (1) DK2525798T3 (es)
ES (1) ES2646829T3 (es)
GB (2) GB2491491B (es)
HK (1) HK1169031A1 (es)
HR (1) HRP20171699T1 (es)
HU (1) HUE035441T2 (es)
LT (1) LT2525798T (es)
NO (1) NO2525798T3 (es)
NZ (1) NZ601255A (es)
PL (1) PL2525798T3 (es)
PT (1) PT2525798T (es)
RS (1) RS56576B1 (es)
RU (1) RU2574022C2 (es)
SG (1) SG181997A1 (es)
SI (1) SI2525798T1 (es)
WO (1) WO2011088503A1 (es)
ZA (1) ZA201205370B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006318349B2 (en) 2005-11-28 2010-08-19 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
DK2785352T3 (da) * 2011-11-29 2020-05-25 Jurox Pty Ltd Stabile injicerbare farmaceutiske sammensætninger omfattende 2-hydroxypropyl-beta-cyclodextrin og alfaxalon
PL2806877T3 (pl) * 2012-01-23 2020-06-01 Sage Therapeutics, Inc. Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
EP3957309A1 (en) * 2012-08-21 2022-02-23 Sage Therapeutics, Inc. Preparation of a composition comprising allopregnanolone and sulfobutylether-beta-cyclodextrin
WO2014071449A1 (en) 2012-11-09 2014-05-15 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
JP2016501876A (ja) * 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
AU2016214996B2 (en) * 2015-02-06 2021-03-04 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
CA3001722A1 (en) * 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
MA43815A (fr) 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
JP6986140B2 (ja) 2018-04-16 2021-12-22 川崎重工業株式会社 ベルトコンベヤ
WO2020006596A1 (en) 2018-07-03 2020-01-09 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and methods of preparation
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2020123551A1 (en) * 2018-12-10 2020-06-18 Halo Science LLC Stable formulations of anesthetics and associated dosage forms
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
JP2023503928A (ja) 2019-12-06 2023-02-01 マリナス ファーマシューティカルズ， インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2062359T3 (es) * 1989-05-24 1994-12-16 Innovet Inc Un procedimiento de preparacion de una composicion anestesica o hipnotica esteroidal hipoalergenica.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
AUPQ633900A0 (en) * 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
WO2002074200A1 (en) * 2001-03-20 2002-09-26 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
AU2006318349B2 (en) * 2005-11-28 2010-08-19 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof

Also Published As

Publication number Publication date
PL2525798T3 (pl) 2018-05-30
BR112012017800B1 (pt) 2020-12-08
CA2786762A1 (en) 2011-07-28
EP2525798B1 (en) 2017-08-09
BR112012017800A2 (pt) 2018-07-10
KR101747476B1 (ko) 2017-06-14
CY1119947T1 (el) 2018-12-12
KR20120136347A (ko) 2012-12-18
BR112012017800A8 (pt) 2018-08-14
SG181997A1 (en) 2012-08-30
RS56576B1 (sr) 2018-02-28
WO2011088503A1 (en) 2011-07-28
US20120316146A1 (en) 2012-12-13
CN102802635B (zh) 2014-07-30
GB2491491B (en) 2014-07-30
AU2011207103A1 (en) 2012-07-26
JP2013517299A (ja) 2013-05-16
GB2491491A (en) 2012-12-05
GB201210657D0 (en) 2012-08-01
NO2525798T3 (es) 2018-01-06
EP2525798A4 (en) 2014-02-19
LT2525798T (lt) 2018-01-10
US8975245B2 (en) 2015-03-10
HRP20171699T1 (hr) 2018-01-26
ES2646829T3 (es) 2017-12-18
US8697678B2 (en) 2014-04-15
HUE035441T2 (en) 2018-05-02
JP5930311B2 (ja) 2016-06-08
NZ601255A (en) 2013-09-27
HK1169031A1 (en) 2013-01-18
CA2786762C (en) 2017-12-05
SI2525798T1 (en) 2018-01-31
GB2484244A (en) 2012-04-04
RU2574022C2 (ru) 2016-01-27
EP2525798A1 (en) 2012-11-28
GB201201842D0 (en) 2012-03-21
US20140066417A1 (en) 2014-03-06
GB2484244B (en) 2012-10-31
CN102802635A (zh) 2012-11-28
PT2525798T (pt) 2017-11-15
DK2525798T3 (da) 2017-11-20
AU2011207103B2 (en) 2013-03-21
ZA201205370B (en) 2013-09-25
RU2012134321A (ru) 2014-02-27

Similar Documents

Publication Publication Date Title
CL2012002032A1 (es) Composición farmacéutica hospedador/huesped de administración inyectable intravenosa anestésica o sedante que comprende un hospedador de ciclodextrina o su forma modificada con un huesped de fármaco anestésico esteroide neuroactivo; método para inducir o mantener la anestesia o sedación; y uso para inducir la anestesia.
BR112013031794A2 (pt) novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos
CL2013000801A1 (es) Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
CL2013000444A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprende un material de liberacion prolongada, y oxicodona y naloxona, cuya composicion farmaceutica almacenada en condiciones de estres tiene menos de un 4% de sustancias relacionadas con oxicodona y naloxona; y uso de un aglutinante para fabricar dicha composicion.
BRPI0917975A2 (pt) formulação de depósito de formação local injetável, processo para a preparação da referida formulação, composição farmacêutica, seringa pré-carregada, e uso de peg500 dme
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
CO6801729A2 (es) Composiciones y métodos para modular el fxr
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
CL2011002877A1 (es) Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
BR112014010670A2 (pt) composição para administração transdérmica de uma progestina, dispositivo de administração de droga transdérmica, e, método para melhorar a estabilidade de uma composição de administração transdérmica
CL2015002534A1 (es) Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada
BR112013015816A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina e uso de uma construção de dna
BR112013012587A2 (pt) composição farmacêutica para administração nasal
BR112012024673A2 (pt) composição anestésica termogelificante
BRPI0815821A2 (pt) Composições e métodos que empregam antagonistas nmda para alcançar um efeito poupador de anestésico.
GT201400090A (es) 2-tiopirimidinonas
BR112013015085A2 (pt) composição farmacêutica, método para preparar uma composição, e, uso de composição
BRPI1010073A2 (pt) composição anticancerígina injetável para administração local contendo hidroxicloquina
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
BRPI1009741A2 (pt) composição, método para prevenir ou tratar a mucosite em paciente mamífero, composição farmacêutica para adminstração tópica, e uso de uma composição
BRPI1005932A2 (pt) composto, composição farmacêutica para inalação e inalador
CL2016001570A1 (es) Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas
CR20130174A (es) Sistema y composiciones mejorados para la administración transbucal de fármacos